Diabetes Mellitus, Type 1 Clinical Trials

Type 1 Diabetes TrialNet, an international network of researchers exploring ways to prevent and delay the progression of type 1 diabetes, is taking great strides for type 1 diabetes. When you get involved in TrialNet research, you become part of a worldwide team that is working to find a way ...

Northern California Research is conducting a study for diabetic peripheral neuropathy (DPN). DPN is a type of nerve damage that can occur if you have diabetes. This study is for men and women who are experiencing painful diabetic peripheral neuropathy in both lower extremities (legs). The specific events that result ...

Primary objective: To demonstrate that morning injection of Toujeo compared to Lantus will provide better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult patients with type 1 diabetes mellitus. Secondary objective(s): To demonstrate that treatment with Toujeo compared to Lantus will provide lower incidence rate of nocturnal symptomatic ...

To perform baseline and repeat assessments over time of the metabolic and immunologic status of individuals at risk for type 1 diabetes to characterize their risk for developing T1D and identify subjects eligible for prevention trials, describe the pathogenic evolution of T1D, and increase the understanding of the pathogenic factors ...

Evaluate LX4211 in type 1 patients with poorly controlled blood sugars.

The healthy insulin-producing beta cells that you have left when you are first diagnosed with type 1 diabetes are precious. The aim of the EXTEND Study is to test whether a therapy called tocilizumab (Actemra®) can stop the immune system from attacking these remaining beta cells and possibly extend the ...

The investigational medication is a potential new type of insulin that is similar to insulin glargine (Lantus®), which you are currently taking. If the investigational medication is approved, it could be a more affordable treatment option, becoming more widely available and benefiting more people with diabetes worldwide. The aim of ...

The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial. All subjects will receive close monitoring for development of AGT or T1DM. Subjects will receive Abatacept or placebo and close monitoring for development of AGT or T1DM. To assess the safety, efficacy, and mode of action of Abatacept ...

The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease. Teplizumab has been studied in new onset type 1 diabetes for testing of efficacy ...

This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects will receive ATG alone and at least 28 subjects will receive placebo alone within 100 days from diagnosis of ...